CRDF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Cardiff Oncology Inc (CRDF) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock lacks clear positive momentum, has weak financials, and no strong trading signals. While analysts provide optimistic long-term price targets, the current technical and financial indicators suggest caution. A hold position is recommended until more positive catalysts emerge or financial performance improves.
The technical indicators are bearish. The MACD histogram is below 0 and negatively contracting, RSI is neutral at 31.755, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). Key support is at 1.51, and resistance is at 1.724. The stock closed at 1.575, slightly below the pivot of 1.617, indicating weakness.
based on the potential of their lead drug candidate, onvansertib, for treating aggressive cancer types. The recent selloff is seen as an attractive entry point by H.C. Wainwright.
is down 1.54%.
In Q3 2025, revenue dropped to $120,000 (-27.27% YoY), net income fell to -$11.26 million (-5.03% YoY), and EPS declined to -$0.17 (-32.00% YoY). Gross margin remained flat at 100%. The financials indicate poor growth trends.
Analysts are optimistic about the long-term potential of Cardiff Oncology. H.C. Wainwright and Noble Capital have buy ratings with price targets of $10 and $12, respectively, based on the potential of their lead drug candidate and future earnings projections. However, these targets are contingent on clinical and regulatory milestones, which carry inherent risks.
